Ubs Group Ag Processa Pharmaceuticals, Inc. Transaction History

Ubs Group Ag

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 09, 2024	BUY	$0.18 - $0.84 $14,276 - $66,625	79,316 Added 11218.67%	80,023 $27,000
Q3 2023 Nov 09, 2023	BUY	$0.24 - $0.53 $169 - $374	707 New	707 $0
Q1 2023 May 12, 2023	BUY	$0.41 - $1.3 $9,208 - $29,196	22,459 New	22,459 $11,000
Q2 2022 Aug 10, 2022	SELL	$1.68 - $3.55 $1,873 - $3,958	-1,115 Closed	0 $0
Q1 2022 May 16, 2022	BUY	$3.01 - $5.21 $2,699 - $4,673	897 Added 411.47%	1,115 $3,000
Q4 2021 Feb 14, 2022	SELL	$4.03 - $8.42 $1,321 - $2,761	-328 Reduced 60.07%	218 $1,000
Q3 2021 Nov 15, 2021	BUY	$5.28 - $8.61 $2,661 - $4,339	504 Added 1200.0%	546 $5,000
Q2 2021 Aug 13, 2021	BUY	$6.15 - $10.95 $258 - $459	42 New	42 $0

Ticker PCSA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 15,856,200
Market Cap $14.3M
Description
Processa Pharmaceuticals, Inc., a clinical stage biopharmaceutical company, focuses on the development of drug products for the treatment of patients with unmet medical needs in the United States. Its lead product candidate is PCS499, an oral tablet that is in Phase 2B clinical trials for the treatment of ulcerative and non-ulcerative necrobiosi...

Get notified when there are updates to the investment portfolio of Ubs Group Ag, based on Form 13F filings with the SEC.

Stay updated on Ubs Group Ag with notifications on news.